The Prostate Cancer Program (Program) of the UCSF Helen Diller Family Comprehensive Cancer (Center) is a multidisciplinary group of investigators focused on understanding the core biology that drives the clinical behavior of prostate cancer across the full spectrum of the disease. The Prostate Cancer Program comprises 25 basic and clinical scientists from nine departments working together to translate research into advances in the epidemiology, prevention, staging, and treatment of prostate cancer. Program faculty represent membership in five graduate programs: Program in Biological Sciences (PIBS);Biomedical Sciences (BMS);Bioengineering, Pharmaceutical Sciences and Pharmacogenomics (PSPG);and Chemical Biology. The goals of the Program are to promote interdisciplinary research that will allow a better understanding ofthe biology of prostate cancer from the biologic and environmental factors associated with carcinogenesis, through the early detection and disease progression to prognostication, and the biologic basis of disease progression. The ultimate goal is the development of novel intervention strategies that will improve the lives of men who carry a diagnosis of prostate cancer or who are at risk of developing prostate cancer. The Prostate Cancer Program pursues these goals through ongoing work in four major thematic areas: (1) Risk and Oncogenesis;(2) Prognosis and Progression;(3) Biology and Therapeutic Targets;and (4) Disparities, Health Related Quality of Life (HRQOL), and Outcomes. The Program has $9,667,568 in total peer reviewed support for the last grant year. The Program has 16% intra-programmatic and 13% inter-programmatic publications.
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
